Skip to content
EVOHN

Stack 05

Cognitive Protocol

Two regulatory neuropeptides with complementary neurotrophic and monoaminergic profiles.

Research domain
Neuro
Components
03
Certification
Per component
Supply
Never pre-mixed
EVOHN Semax
EVOHN Selank
EVOHN NAD+

Overview

What this grouping is

Semax and Selank are the two most extensively documented members of the Russian regulatory-peptide series, and they are rarely studied apart. Both are short peptides stabilised by a proline-glycine-proline extension; both act on neurotrophic expression; neither does so by the same route.

The grouping is assembled for comparative neuropeptide work — the case where the question is not whether a peptide has an effect, but which of two mechanisms accounts for it.

Purpose

To place two mechanistically distinct regulatory neuropeptides in one comparative frame with a shared stabilising architecture.

Included peptides

03 independently certified vials

Each component carries its own batch number and its own certificate of analysis. A stack result is only traceable if every batch identifier is recorded.

  • 01

    Semax

    10 mg / vial

    Neurotrophic arm — BDNF and NGF expression, monoaminergic signalling.

    Assayed purity99.66%
    98%Spec ≥ 99%100%
  • 02

    Selank

    10 mg / vial

    Regulatory arm — enkephalin degradation kinetics, GABAergic expression.

    Assayed purity99.74%
    98%Spec ≥ 99%100%
  • 03

    NAD+

    500 mg / vial

    Energy context — neuronal mitochondrial capacity as a covariate.

    Assayed purity99.17%
    98%Spec ≥ 99%100%

Scientific summary

Semax is characterised as an ACTH(4-10) analogue that raises BDNF and NGF transcript levels in hippocampal and cortical preparations without the adrenocorticotropic activity of the parent fragment, with additional work on dopaminergic and serotonergic signalling. Selank derives from the immunomodulatory tetrapeptide tuftsin and is examined for inhibition of enkephalin-degrading enzymes alongside changes in GABAergic and serotonergic gene expression. Both share the proline-glycine-proline extension that confers peptidase resistance — which makes the pair a natural control for one another on stability while differing on mechanism.

Ideal research use

  • 01Neurotrophic factor expression assays
  • 02Comparative regulatory peptide characterisation
  • 03Central nervous system model development
  • 04Peptide stability studies where the PGP extension is the variable

Protocol information

How the set is handled

A description of laboratory practice as the published record reports it. Nothing here is administration guidance, and none of it should be read as such.

  1. 01Comparative designBecause both compounds share the same stabilising extension, published designs often use one as the stability control for the other, isolating mechanism from pharmacokinetics.
  2. 02ReconstitutionBoth are readily soluble in water and tolerate conventional handling. Neither is notably light- or oxidation-sensitive, which is unusual in this catalogue and simplifies session planning.
  3. 03SequencingWhere both are examined in one model, the literature commonly runs them in separate arms before any combined arm, so that overlapping monoaminergic effects can be attributed correctly.
  4. 04DocumentationRecord purity for both. Sequence-confirmed identity matters particularly here, because the two share a structural motif and a purity figure alone does not establish which peptide is in the vial.

Storage

Every component is supplied lyophilised and is stored independently at −20 °C, protected from light and moisture. Components are not pre-mixed: each vial carries its own batch number and its own certificate of analysis, and each is reconstituted separately. Once in solution, hold at 2–8 °C and observe the interval stated on the batch certificate for that specific component — the shortest interval in the group governs the group.

Storage & handling guide

Frequently asked

About this grouping

This catalogue is presented for informational purposes only. It is not an offer of sale, and it makes no medical or therapeutic claim.

Enquiries

Discuss the protocol.

Ask a specialist about the Cognitive Protocol — component batches, current documentation, and what can be supplied to your territory.